## Converge Bio Focuses on AI for Drug Discovery Converge Bio, a startup focused on applying artificial intelligence to drug discovery, has secured $25 million in Series A funding. The round was led by Bessemer Venture Partners, with support from prominent figures from leading technology companies such as Meta, OpenAI, and Wiz. This investment represents a significant step forward for Converge Bio, allowing it to accelerate the development of its AI platform and expand its research activities. The use of artificial intelligence in drug discovery is becoming increasingly widespread, thanks to its ability to analyze large amounts of data and identify potential drug candidates more quickly and efficiently than traditional methods. AI is expected to radically transform the pharmaceutical industry, reducing the time and costs required to bring new drugs to market.